CRISPR Therapeutics reports Q1 net loss of $53.1M; exa-cel submissions complete in US, EU, UK

CRISPR Therapeutics AG

2023-Q1 EPS reported -$0.67 revenue$100,000,000

Revenue of $100.0M from Vertex upfront; net loss improved to $53.1M vs $179.2M in Q1 2022.
Cash and securities $1,889.5M; R&D expenses $99.9M, G&A $22.4M.
Completed rolling BLAs for exa-cel in SCD and TDT; EMA and MHRA submissions validated.
Initiated clinical trials for next-gen CAR T candidates CTX112 (CD19) and CTX131 (CD70).
Appointed Raju Prasad as CFO; Brad Bolzon left board; Vertex deal includes $100M upfront and up to $230M milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRISPR Therapeutics AG reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-23-018790

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.